World tennis superstar Novak Djokovic reportedly has an 80% stake in QuantBioRes that’s currently working on finding a treatment, not a vaccine, for COVID-19.
The funds will be used to advance the firm’s precision oncology research efforts and pipeline, particularly those involving the creation of alteration-specific therapies.
The FDA issued the partial clinical hold order in response to the IND application Yumanity submitted in December last year. The company expects additional data on the directive within the next 30 days.
The new pancreatic cancer vaccine from ImmunityBio shows very promising results. Here’s what you need to know about the vaccine and its result from the tests.
Moderna is poised to commercialize its COVID-19 and influenza combination vaccine by the fall of 2023, with some potential for the same drug to also be viable against the RSV.
GlaxoSmithKline has declined all three of Unilever PLC’s offers to acquire its Consumer Healthcare business, saying that the proposal undervalued the division’s present and further worth.
Relief said that NRx’s claims that their partnership has been canceled were untrue and that it believes their collaboration involving aviptadil remains active and in full force.
The job cuts were announced as part of an organizational streamlining initiative that will refocus resources toward the company’s highest-value activities.
Sanofi will pay ABL $75 million upfront, and the latter is eligible to receive as much as $985 million down the line as development, regulatory, and commercialization milestones are met.
Sarepta Therapeutics shared positive topline results from its ongoing SRP-9001-102 study on the effectiveness of delandistrogene moxeparvovec in treating Duchenne muscular dystrophy.
